Literature DB >> 6704303

Effect of the nitroimidazole Ro 03-8799 on the activity of chemotherapeutic agents against a murine tumour in vivo.

P W Sheldon, P Gibson.   

Abstract

The effect of the 2-nitroimidazole Ro 03-8799 (8799) on the activity of 11 chemotherapeutic agents against the anaplastic MT tumour in mice has been determined by soft agar cloning. The 8799, whilst producing little cytotoxicity by itself, potentiated the cytotoxic actions of the alkylating agents melphalan and cyclophosphamide, and the nitrosoureas BCNU, CCNU and MeCCNU. This potentiation was influenced by the time interval between the administration of 8799 and the chemotherapeutic agents, and also by the site of tumour implantation. However, 8799 did not potentiate the cytotoxicities of the compounds CBDCA, cisplatin, adriamycin, vincristine, 5-fluorouracil and bleomycin. A review is included of the reported in vivo effects of nitroimidazoles on the chemotherapeutic agents investigated here.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6704303      PMCID: PMC1976734          DOI: 10.1038/bjc.1984.46

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.

Authors:  R P Hill; J A Stanley
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

2.  Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo.

Authors:  N E Sladek
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

3.  Resistance to adriamycin in multicellular spheroids.

Authors:  R M Sutherland; H A Eddy; B Bareham; K Reich; D Vanantwerp
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-08       Impact factor: 7.038

4.  The cytocidal action of metronidazole in combination with other antineoplastic agents.

Authors:  J P Kelly; T W Hannam; G R Giles
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

5.  Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.

Authors:  J J Clement; M S Gorman; I Wodinsky; R Catane; R K Johnson
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

6.  Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.

Authors:  T C Stephens; V D Courtenay; J Mills; J H Peacock; C M Rose; D Spooner
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

7.  In vivo combination of misonidazole and the chemotherapeutic agent CCNU.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

8.  In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.

Authors:  I F Tannock
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640

9.  In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin.

Authors:  I F Tannock
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640

10.  In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.

Authors:  R T Mulcahy; D W Siemann; R M Sutherland
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

View more
  1 in total

1.  Misonidazole reduces blood flow in two experimental murine tumours.

Authors:  J C Murray; V S Randhawa
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.